Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

[1]  E. Kerwin,et al.  Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) , 2019, Respiratory research.

[2]  B. Darpo,et al.  Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study , 2019, Clinical pharmacology in drug development.

[3]  G. Feldman,et al.  Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. , 2019, Pulmonary pharmacology & therapeutics.

[4]  E. Kerwin,et al.  Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. , 2019, Respiratory medicine.

[5]  G. Feldman,et al.  Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. , 2019, Chronic obstructive pulmonary diseases.

[6]  Junyan Wu,et al.  Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis , 2018, British Medical Journal.

[7]  E. Kerwin,et al.  EFFICACY OF REVEFENACIN, A LONG-ACTING MUSCARINIC ANTAGONIST FOR NEBULIZED THERAPY, IN COPD PATIENTS WITH MARKERS OF MORE SEVERE DISEASE , 2018, Chest.

[8]  Dave Singh,et al.  Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. , 2018, Pulmonary pharmacology & therapeutics.

[9]  G. Ferguson,et al.  Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors. , 2018, Chronic obstructive pulmonary diseases.

[10]  Ich Q3DR.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS , 2018 .

[11]  E. Kerwin,et al.  Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. , 2017, Respiratory medicine.

[12]  D. Tashkin.  A review of nebulized drug delivery in COPD , 2016, International journal of chronic obstructive pulmonary disease.

[13]  M. Mammen,et al.  Duration by Design: Discovery of Revefenacin, the First-in-Class Nebulized Once-Daily Bronchodilator for the Treatment of Patients With COPD , 2016 .

[14]  Niels H Chavannes,et al.  Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study , 2016, PloS one.

[15]  C. Vogelmeier,et al.  Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study , 2016, European Respiratory Journal.

[16]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[17]  J. Wedzicha,et al.  Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies , 2016, COPD.

[18]  C. Vogelmeier,et al.  Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD® , 2015, Advances in Therapy.

[19]  H. Mansour,et al.  Dry powder inhalers in COPD, lung inflammation and pulmonary infections , 2015, Expert opinion on drug delivery.

[20]  F. Herth,et al.  Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease , 2014, Respiration.

[21]  H. Satoh,et al.  Use of tiotropium in patients with COPD aged 80 years and older , 2013, Experimental and therapeutic medicine.

[22]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[23]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[24]  Ruben D. Restrepo,et al.  The Role of Nebulized Therapy in the Management of COPD: Evidence and Recommendations , 2012, COPD.

[25]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[26]  P. Ind,et al.  Inhaled therapy in elderly COPD patients; time for re-evaluation? , 2007, Age and ageing.

[27]  J. Oppenheimer.  Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines , 2006 .

[28]  D. Mahler,et al.  The MCID of the Transition Dyspnea Index is a Total Score of One Unit , 2005, COPD.

[29]  P. Jones.  St. George's Respiratory Questionnaire: MCID , 2005, COPD.

[30]  J. L. Rau,et al.  Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. , 2005, Chest.

[31]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[32]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[33]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.